Skip to main content
    L

    Lifecore Biomedical Inc. (LFCR)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $6.42
    -0.01 (-0.08%)

    Market Cap: $243.36M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Lifecore Biomedical Inc. (LFCR) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Lifecore Biomedical (LFCR) is expected to report earnings on Feb 5, 2027. In the quarter ended Aug 31, 2026, Lifecore Biomedical reported EPS of -$1.08, below the -$0.30 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    29%(11/38)
    Avg Surprise
    -52.38%

    Upcoming Estimates

    Results pendingPeriod ending Jun 30, 2026
    EPS Consensus-$0.22
    Range-$0.30 - -$0.17
    4 analysts
    EPS Revisions
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.21-4.7%
    60d ago-$0.220.0%
    30d ago-$0.220.0%
    7d ago-$0.220.0%
    Current-$0.22
    Revenue Consensus
    $32.02M
    Range$30.80M - $32.98M
    5 analysts
    Results pendingPeriod ending Sep 30, 2026
    EPS Consensus-$0.30
    Range-$0.33 - -$0.26
    4 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.22-36.8%
    60d ago-$0.300.0%
    30d ago-$0.300.0%
    7d ago-$0.31+4.0%
    Current-$0.30
    Revenue Consensus
    $25.57M
    Range$24.89M - $26.20M
    5 analysts

    Next Report

    LFCR has an expected report date of Feb 5, 2027.

    LFCR Earnings Call

    The latest LFCR earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, LFCR beat 11, missed 21 and matched 6. The widest gap in the table came in the quarter ended May 31, 2021, when EPS landed 800.00% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Aug 31, 2026-$1.08-$0.30N/A-260.00%MissN/AN/AN/ANov 4, 2026N/A
    May 31, 2026-$0.19-$0.17N/A-11.76%MissN/AN/AN/AAug 5, 2026N/A
    Feb 28, 2026-$0.16-$0.23N/A+30.43%BeatN/A10 up, 1 downMar 16, 2026$23.19M
    Nov 30, 2025Not reported-$0.16N/AN/ANot reportedN/A10 up, 1 downJan 1, 2026$34.17M
    Aug 31, 2025-$0.43-$0.30-$0.34 - -$0.28-43.33%MissN/A40 up, 1 downNov 6, 2025$23.19M
    May 31, 2025-$0.10-$0.09-$0.10 - -$0.09-11.11%MissN/A20 up, 2 downAug 7, 2025$36.44M
    Feb 28, 2025-$0.47-$0.15-$0.16 - -$0.14-213.33%Miss-211.9%22 up, 1 downApr 3, 2025$35.15M
    Nov 30, 2024-$0.20-$0.30-$0.34 - -$0.27+33.33%BeatN/A20 up, 1 downJan 2, 2025$32.56M
    Aug 31, 2024-$0.37-$0.46-$0.47 - -$0.46+19.57%BeatN/A20 up, 0 downOct 4, 2024$24.70M
    May 31, 2024-$0.17-$0.12-$0.12 - -$0.12-41.67%MissN/A10 up, 0 downAug 26, 2024$37.88M
    Feb 29, 2024$0.42$0.13N/A+223.08%BeatN/AN/AN/AMay 22, 2024$35.70M
    Nov 30, 2023-$0.13-$0.23N/A+43.48%BeatN/A20 up, 0 downDec 29, 2023$30.15M
    Aug 31, 2023-$1.19-$0.23-$0.39 - -$0.13-418.13%MissN/A20 up, 0 downNov 14, 2023$24.52M
    May 31, 2023-$0.11-$0.07-$0.82 - $0.07-57.14%MissN/A20 up, 0 downJun 1, 2023$31.14M
    Feb 28, 2023-$0.42-$0.11N/A-281.82%MissN/A10 up, 0 downMar 16, 2023$26.54M
    Nov 30, 2022-$0.21-$0.04-$0.06 - -$0.02-425.00%MissN/A20 up, 0 downFeb 27, 2023$21.86M
    Aug 31, 2022-$0.32-$0.13N/A-146.15%MissN/AN/AN/AOct 6, 2022$23.72M
    May 31, 2022-$0.01-$0.01N/A0.00%In line-114.3%N/AN/AAug 10, 2022N/A
    Feb 28, 2022-$0.08-$0.03N/A-166.67%MissN/AN/AN/AApr 5, 2022$37.40M
    Nov 30, 2021-$0.22-$0.09N/A-144.44%Miss-1200.0%N/AN/AJan 5, 2022$43.45M
    Aug 31, 2021-$0.23-$0.12N/A-91.67%MissN/AN/AN/ASep 29, 2021$43.35M
    May 31, 2021$0.07-$0.01N/A+800.00%Beat+40.0%N/AN/AJul 28, 2021N/A
    Feb 28, 2021-$0.19$0.04N/A-575.00%MissN/AN/AN/AApr 7, 2021$44.69M
    Nov 30, 2020$0.02$0.03N/A-33.33%MissN/AN/AN/AJan 6, 2021$130.90M
    Aug 31, 2020-$0.38-$0.13N/A-192.31%MissN/AN/AN/AOct 6, 2020$135.64M
    May 31, 2020$0.05$0.03N/A+66.67%BeatN/AN/AN/AAug 11, 2020N/A
    Feb 29, 2020-$0.39-$0.01N/AN/AN/A-1075.0%N/AN/AMar 31, 2020$152.93M
    Nov 30, 2019-$0.16-$0.06N/A-166.67%MissN/AN/AN/AJan 2, 2020$142.59M
    Aug 31, 2019-$0.16-$0.16N/A0.00%In line-1700.0%N/AN/AOct 1, 2019$138.71M
    May 31, 2019-$0.01-$0.02N/A+50.00%Beat-104.2%N/AN/AJul 30, 2019$152.78M
    Feb 28, 2019$0.04$0.05N/A-20.00%Miss-55.6%N/AN/AApr 3, 2019$155.55M
    Nov 30, 2018-$0.02-$0.02N/A0.00%In line-200.0%N/AN/AJan 3, 2019$124.56M
    Aug 31, 2018$0.01$0.06N/A-83.33%Miss-87.5%N/AN/AOct 2, 2018$124.67M
    May 31, 2018$0.24$0.22N/A+9.09%Beat+166.7%N/AN/AJul 31, 2018$141.08M
    Feb 28, 2018$0.09$0.09N/A0.00%In line-50.0%N/AN/AApr 3, 2018$144.91M
    Nov 30, 2017$0.02$0.01N/A+100.00%Beat-60.0%N/AN/AJan 3, 2018$122.46M
    Aug 31, 2017$0.08$0.06N/A+33.33%Beat-33.3%N/AN/ASep 26, 2017$115.78M
    May 31, 2017$0.09$0.09N/A0.00%In line-47.1%N/AN/AJul 25, 2017$64.95M
    Feb 28, 2017$0.18$0.18N/A0.00%In lineN/AN/AN/AApr 4, 2017$136.57M
    Nov 30, 2016$0.05$0.06N/A-16.67%Miss-28.6%N/AN/AJan 4, 2017$135.87M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended May 31, 2026 was -$0.78, after -$1.14 the year before. It was $0.44 for the year ended May 31, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    May 31, 2026-$0.78N/A
    May 31, 2025-$1.14N/A
    May 31, 2024-$1.07N/A
    May 31, 2023-$1.06N/A
    May 31, 2022-$0.54N/A
    May 31, 2021-$0.48N/A
    May 31, 2020-$0.66-3400.0%
    May 31, 2019$0.02-95.3%
    May 31, 2018$0.43N/A
    May 31, 2017$0.44N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,900 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20264,8549
    2025Q4Dec 31, 20256,3789
    2025Q3Sep 30, 20254,1276
    2025Q2Jun 30, 20254,4127
    2025Q1Mar 31, 20253,8977
    2024Q4Dec 31, 20243,9786

    2026Q2 Earnings Call

    Opening remarks

    Stephanie Diaz Manager of Investor Relations Good morning, and thank you for joining us. Today, Lifecore Biomedical will provide its earnings results for the second quarter and 6 months ended June 30, 2026, and a corporate update. As the company has recently changed its fiscal year end to align with the calendar year, we will be comparing our results for the second quarter ended June 30, 2026, with the comparable prior year quarter ended May 25, 2025. For the 6-month period, we will be comparing our results from January 1 through June 30, 2026, with the prior year period from November 24, 2024, through May 25, 2025. Hosting the call today from Lifecore are Paul Josephs, President and Chief Executive Officer; and Ryan Lake, Chief Financial Officer. Before we begin, I'd like to remind everyone that today's conference call will contain forward-looking statements. It is important to note that the forward-looking statements made during this call reflect management's judgment and analysis only as of today, August 5, 2026, and the company's actual results could differ materially from those projected in such forward-looking statements. For a more thorough discussion of the risks and uncertainties associated with any forward-looking statements, please see the disclaimer regarding forward-looking statements that is included in our earnings press release, which was furnished to the Securities and Exchange Commission this morning on Form 8-K and is available on our corporate website at lifecore.com as well as our other filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-Q for Q2 2026, which was filed with the SEC this morning and is also available on our website. In addition, our earnings press release includes a discussion of, and during this call we will reference, certain non-GAAP financial information. You can find relevant non-GAAP reconciliations in our press release. With that, I'd like to turn the call over to Paul Josephs, President and Chief Executive Officer.

    Paul Josephs President and Chief Executive Officer Thank you, Stephanie. Good morning, everyone, and thank you for joining us today. During the second quarter, Lifecore continued to execute with focus and discipline against the strategic objectives we implemented over the last 24 months. We are energized by the success and progress we are making in achieving the three pillars of our growth strategy. As a reminder, these pillars are maximizing our existing commercial business, advancing our development pipeline towards commercialization and adding high-quality new programs to our pipeline through business development. This is a thoughtful and deliberate strategy that is designed to drive durable growth over the medium to long term and create value for our shareholders as well as our employees, customers and other key stakeholders.

    Frequently Asked Questions About LFCR

    When is Lifecore Biomedical's next earnings date?

    Lifecore Biomedical's next earnings report is expected for Feb 5, 2027.

    Did LFCR beat earnings estimates last quarter?

    No. Lifecore Biomedical reported EPS of -$1.08 for the quarter ended Aug 31, 2026, below the -$0.30 estimate by 260.00%.

    What EPS do analysts expect from LFCR next quarter?

    The consensus EPS estimate for Lifecore Biomedical for the quarter ended Sep 30, 2026 is -$0.30 from 4 analysts, with estimates from -$0.33 to -$0.26.

    How often does LFCR beat earnings estimates?

    Lifecore Biomedical beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -57.03%.